Disseminated pulmonary TB, lower BMI, WHO clinical stage 4 and lower CD4 count were found to be associated with increased risk of developing anti-TB drugs induced hepatotoxicity on bivariate analyses. The gene discussed is CD4; the disease is tuberculosis.